BMO Capital analyst Alex Arfaei offered some initial thoughts from Valeant Pharmaceuticals' (NYSE: VRX) conference call to address recent allegations ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Valeant (VRX) Answered Its Questions Well, But Other Questions Remain - Deutsche Bank October 26, 2015 11:15 AM UPDATE: Valeant Pharma (VRX) Sees Dramatic Red-to-Green Reversal Then Collapses AgainOctober 26, 2015 9:40 AM Pre-Open Stock Movers 10/26: (PNY) (QUNR) (PBY) Higher; (AKS) (VRX) (AXP) Lower (more...)October 26, 2015 9:31 AM Mizuho Provides Quick Thoughts on Valeant (VRX) Slides/CallOctober 26, 2015 9:14 AM Valeant Pharma (VRX) CEO Pearson, Outside Director Ingram Issue Commentary on PhilidorOctober 26, 2015 9:11 AM Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant PharmaceuticalsOctober 26, 2015 9:00 AM Valeant Pharma (VRX) says ad hoc committee will review issues brought up in today's WSJOctober 26, 2015 8:43 AM Drugmaker Valeant raises detailed defense but doubts remainOctober 26, 2015 8:36 AM Valeant Pharma (VRX) Regains Some Early Losses as Conference Call StartsOctober 26, 2015 8:09 AM Dow, S&P 500 end down slightly as Apple, energy weighOctober 26, 2015 7:36 AM Valeant Pharma (VRX) Files Presentation on Philidor; Says No Evidence of Illegal Activity To-DateOctober 26, 2015 7:28 AM Valeant Pharma (VRX) Releases Slides Ahead of Investor Conference CallOctober 26, 2015 7:28 AM WSJ Highlights More 'Smoke' at Valeant Pharma (VRX) Ahead of Conference CallOctober 26, 2015 6:39 AM Valeant Pharma (VRX) Says Philidor Accounting is AppropriateOctober 26, 2015 6:16 AM